151 related articles for article (PubMed ID: 36842815)
21. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M; Ozasa H; Tsuji T; Funazo T; Yoshida H; Hashimoto K; Hosoya K; Ogimoto T; Ajimizu H; Yoshida H; Itotani R; Sakamori Y; Kuninaga K; Aoki W; Hirai T
Cancer Sci; 2023 Feb; 114(2):546-560. PubMed ID: 36285485
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
24. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
26. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
[TBL] [Abstract][Full Text] [Related]
27. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
28. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N; Gillis R; Kilickap S; Froesch P; Orlov S; Filippova E; Demirci U; Christopoulos P; Cicin I; Basal FB; Yilmaz C; Fedor M; Korkmaz T; Paydas S; Gautschi O; Zirtiloglu A; Eralp Y; Cinkir HY; Sezer A; Erman M; Tural D; Turna H; Mazieres J; Dudnik E; Reguart N; Camidge DR; Ng TL; Şenler FÇ; Beypınar İ; Yazılıtaş D; Demirkazık A; Karaoğlu A; Okutur K; Coşkun HŞ; Şendur MAN; Isikdogan A; Cabuk D; Yumuk PF; Yıldız I; Kaplan MA; Özyılkan Ö; Öztop İ; Olmez OF; Aydin K; Aydıner A; Meydan N; Grinberg RD; Roisman LC
Lung Cancer; 2020 Oct; 148():48-54. PubMed ID: 32799090
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Chen J; O'Gorman MT; James LP; Klamerus KJ; Mugundu G; Pithavala YK
Clin Pharmacokinet; 2021 Oct; 60(10):1313-1324. PubMed ID: 33937954
[TBL] [Abstract][Full Text] [Related]
30. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
31. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
32. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
33. An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021).
Liu M; Dai J; Wei M; Pan Q; Zhu W
Expert Opin Ther Pat; 2022 Jun; 32(6):713-729. PubMed ID: 35343863
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy.
Li Y; Lv Y; Zhang C; Fu B; Liu Y; Hu J
Eur J Med Chem; 2023 Sep; 257():115477. PubMed ID: 37210839
[TBL] [Abstract][Full Text] [Related]
35. A user's guide to lorlatinib.
Nagasaka M; Ge Y; Sukari A; Kukreja G; Ou SI
Crit Rev Oncol Hematol; 2020 Jul; 151():102969. PubMed ID: 32416346
[TBL] [Abstract][Full Text] [Related]
36. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
Chin LP; Soo RA; Soong R; Ou SH
J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
[TBL] [Abstract][Full Text] [Related]
37. Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Barata F; Aguiar C; Marques TR; Marques JB; Hespanhol V
Drug Saf; 2021 Aug; 44(8):825-834. PubMed ID: 34080177
[TBL] [Abstract][Full Text] [Related]
38. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T
Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160
[TBL] [Abstract][Full Text] [Related]
40. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]